BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 18796328)

  • 1. RANKL-induced schlafen2 is a positive regulator of osteoclastogenesis.
    Lee NK; Choi HK; Yoo HJ; Shin J; Lee SY
    Cell Signal; 2008 Dec; 20(12):2302-8. PubMed ID: 18796328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.
    Mohamed SG; Sugiyama E; Shinoda K; Taki H; Hounoki H; Abdel-Aziz HO; Maruyama M; Kobayashi M; Ogawa H; Miyahara T
    Bone; 2007 Oct; 41(4):592-602. PubMed ID: 17627913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RGS18 acts as a negative regulator of osteoclastogenesis by modulating the acid-sensing OGR1/NFAT signaling pathway.
    Iwai K; Koike M; Ohshima S; Miyatake K; Uchiyama Y; Saeki Y; Ishii M
    J Bone Miner Res; 2007 Oct; 22(10):1612-20. PubMed ID: 17576169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.
    Yang J; Park OJ; Lee YJ; Jung HM; Woo KM; Choi Y
    Eur J Immunol; 2008 Jun; 38(6):1598-609. PubMed ID: 18421790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldehydic components of cinnamon bark extract suppresses RANKL-induced osteoclastogenesis through NFATc1 downregulation.
    Tsuji-Naito K
    Bioorg Med Chem; 2008 Oct; 16(20):9176-83. PubMed ID: 18823786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of NFAT binding sites that mediate stimulation of cathepsin K promoter activity by RANK ligand.
    Balkan W; Martinez AF; Fernandez I; Rodriguez MA; Pang M; Troen BR
    Gene; 2009 Oct; 446(2):90-8. PubMed ID: 19563866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T; Lee HL; Cha JH; Ko SI; Kim HJ; Shin HI; Woo KM; Ryoo HM; Kim GS; Baek JH
    J Cell Physiol; 2008 Nov; 217(2):409-22. PubMed ID: 18543257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeic acid phenethyl ester inhibits osteoclastogenesis by suppressing NF kappaB and downregulating NFATc1 and c-Fos.
    Ha J; Choi HS; Lee Y; Lee ZH; Kim HH
    Int Immunopharmacol; 2009 Jun; 9(6):774-80. PubMed ID: 19285574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AP-1 stimulates the cathepsin K promoter in RAW 264.7 cells.
    Pang M; Martinez AF; Fernandez I; Balkan W; Troen BR
    Gene; 2007 Nov; 403(1-2):151-8. PubMed ID: 17897792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class II transactivator negatively regulates RANKL-mediated osteoclast differentiation by downregulating NFATc1 and OSCAR.
    Kim JH; Kim K; Youn BU; Jin HM; Kim N
    Cell Signal; 2010 Sep; 22(9):1341-9. PubMed ID: 20466061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation.
    Ikeda F; Nishimura R; Matsubara T; Tanaka S; Inoue J; Reddy SV; Hata K; Yamashita K; Hiraga T; Watanabe T; Kukita T; Yoshioka K; Rao A; Yoneda T
    J Clin Invest; 2004 Aug; 114(4):475-84. PubMed ID: 15314684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY; Lin HY; Fong YC; Wu JB; Chen YF; Tsuzuki M; Tang CH
    Eur J Pharmacol; 2008 Jun; 588(1):124-33. PubMed ID: 18495114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway.
    Huang H; Chang EJ; Ryu J; Lee ZH; Lee Y; Kim HH
    Biochem Biophys Res Commun; 2006 Dec; 351(1):99-105. PubMed ID: 17052691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of osteoclast differentiation and function by the CaMK-CREB pathway.
    Sato K; Suematsu A; Nakashima T; Takemoto-Kimura S; Aoki K; Morishita Y; Asahara H; Ohya K; Yamaguchi A; Takai T; Kodama T; Chatila TA; Bito H; Takayanagi H
    Nat Med; 2006 Dec; 12(12):1410-6. PubMed ID: 17128269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Filamin A regulates monocyte migration through Rho small GTPases during osteoclastogenesis.
    Leung R; Wang Y; Cuddy K; Sun C; Magalhaes J; Grynpas M; Glogauer M
    J Bone Miner Res; 2010 May; 25(5):1077-91. PubMed ID: 19929439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High extracellular calcium-induced NFATc3 regulates the expression of receptor activator of NF-κB ligand in osteoblasts.
    Lee HL; Bae OY; Baek KH; Kwon A; Hwang HR; Qadir AS; Park HJ; Woo KM; Ryoo HM; Baek JH
    Bone; 2011 Aug; 49(2):242-9. PubMed ID: 21514407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.
    Park CK; Lee Y; Chang EJ; Lee MH; Yoon JH; Ryu JH; Kim HH
    Biochem Pharmacol; 2008 Jun; 75(11):2175-82. PubMed ID: 18433733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.
    Kim K; Kim JH; Youn BU; Jin HM; Kim N
    J Immunol; 2010 Dec; 185(12):7460-6. PubMed ID: 21068407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY; Yang D; Chang EJ; Lee Y; Huang H; Sung SH; Lee ZH; Kim YC; Kim HH
    Biochem Pharmacol; 2007 Sep; 74(6):911-23. PubMed ID: 17662251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation.
    Song I; Kim JH; Kim K; Jin HM; Youn BU; Kim N
    FEBS Lett; 2009 Jul; 583(14):2435-40. PubMed ID: 19576893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.